ACT now - With caution - For malaria treatments

Lancet Infectious Diseases

Volumn 3, Issue 10, 2003, Pages 609-

  Bhasin, Virendra K ^a   Nair, Lathika ^a  

^a UNIVERSITY OF DELHI   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMISIN; CHLOROQUINE;

AFRICA; CHEMOPROPHYLAXIS; HUMAN; INFECTION CONTROL; INFECTION RISK; MALARIA CONTROL; MALARIA FALCIPARUM; NONHUMAN; PLASMODIUM MALARIAE; PRIORITY JOURNAL; SHORT SURVEY; TREATMENT FAILURE; WORLD HEALTH ORGANIZATION;

EID: 0141534262     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(03)00767-9     Document Type: Letter

References (5)

1. A single agenda needed for malaria. Lancet Infect Dis 2003; 2: 317.
2. Foster S. Treatment of malaria outside the formal health services. J Trop Med Hyg 1995; 98: 29-34.
3. World Health Organization. The use of artemisinin and its derivatives as antimalarial drugs. Report of a joint CTD/DMP/TDR informal consultation. Geneva: WHO, experts committee; 1998 June. Report no. WHO/MAL/98.1086.
4. Inselberg J. Induction and isolation of artemisinin-resistant mutants of Plasmodium falciparum. Am J Trop Med Hyg 1985; 34: 417-18.
5. Peters W, Robinson BL, Rossier JC, Misra D, Jefford CW, Rossiter JC. The chemotherapy of rodent malaria. XLIX. The activities of some synthetic 1,2,4-trioxanes against chloroquine sensitive and chloyoquine-resistant parasites. Part 2: Structure activity studies on cis-fused cydopenteno-1,2,4-trioxanes (fenozans) against drug-sensitive and drug-resistant lines of Plasmodium berghei and P yoelii spp. Ann Trop Med Parasitol 1993; 87: 9-16.